BETA

IPO registrations (S-1, F-1) · Registrants

Histogen Inc.

SEC CIK
1383701 · filings on EDGAR ↗
Former names
Conatus Pharmaceuticals Inc. (2014–2020); Conatus Pharmaceuticals Inc (2006–2014)
Registration
Form S-1, first filed 2013-06-14, last 2020-12-29; 2 initial registrations, 4 amendments
Outcome
Final prospectus filed 2013-07-25; declared effective 2013-07-24
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
10655 SORRENTO VALLEY ROAD, SUITE 200, San Diego, CA 92121
EIN
20-3183915
EDGAR entity type
operating
Insiders and CEO pay
Histogen Inc. on the corporate pages

Offering terms

Proposed price range
$10.00–$12.00 per share (S-1/A filed 2013-07-23)
Final price
$11.00 per share, within the range (424B4 filed 2013-07-25, an initial public offering)
Shares sold
6,000,000
Gross proceeds
$66,000,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol CNAT
Lead underwriters
Stifel (2,100,000 shares)
Syndicate
Piper Sandler (2,100,000); JMP Securities (1,200,000); Truist Securities (600,000)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 18

FiledFormWhat it isName as filedEDGAR
2013-06-14S-1S-1 (registration)Conatus Pharmaceuticals Inc0001193125-13-258411 ↗
2013-07-01S-1/AS-1/A (amendment)Conatus Pharmaceuticals Inc0001193125-13-278036 ↗
2013-07-08S-1/AS-1/A (amendment)Conatus Pharmaceuticals Inc0001193125-13-284983 ↗
2013-07-23S-1/AS-1/A (amendment)Conatus Pharmaceuticals Inc0001193125-13-298918 ↗
2013-07-24EFFECTEFFECT (declared effective)Conatus Pharmaceuticals Inc9999999995-13-002182 ↗
2013-07-25S-1MEFS-1MEF (added securities)Conatus Pharmaceuticals Inc0001193125-13-301361 ↗
2013-07-25424B4424B4 (final prospectus)Conatus Pharmaceuticals Inc0001193125-13-302836 ↗
2014-08-25EFFECTEFFECT (declared effective)Conatus Pharmaceuticals Inc.9999999995-14-002603 ↗
2017-11-09EFFECTEFFECT (declared effective)Conatus Pharmaceuticals Inc.9999999995-17-002939 ↗
2020-04-01EFFECTEFFECT (declared effective)Conatus Pharmaceuticals Inc.9999999995-20-000660 ↗
2020-08-26EFFECTEFFECT (declared effective)Histogen Inc.9999999995-20-002269 ↗
2020-12-18S-1S-1 (registration)Histogen Inc.0001193125-20-321487 ↗
2020-12-29S-1/AS-1/A (amendment)Histogen Inc.0001193125-20-328744 ↗
2020-12-30S-1MEFS-1MEF (added securities)Histogen Inc.0001193125-20-330140 ↗
2020-12-30EFFECTEFFECT (declared effective)Histogen Inc.9999999995-20-003710 ↗
2021-01-04424B4424B4 (final prospectus)Histogen Inc.0001193125-21-001104 ↗
2022-01-05EFFECTEFFECT (declared effective)Histogen Inc.9999999995-22-000050 ↗
2022-08-03EFFECTEFFECT (declared effective)Histogen Inc.9999999995-22-002240 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2013-07-23S-1/Aregistration statement$10.00–$12.005,000,000-Nasdaq CNAT4primary document; range, shares headline, cover names 4document ↗
2013-07-25424B4final prospectus$11.006,000,000$66,000,000Nasdaq CNAT4primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Aberdare GP III, L.L.C.Other; TenPercentOwner32013–2014
Aberdare Partners III LPOther; TenPercentOwner32013–2014
Aberdare Ventures III LPOther; TenPercentOwner32013–2014
ADVENT VENTURE PARTNERS LLPTenPercentOwner32013
BURGESS GARY C.OfficerSr. VP, Clin. Res. & CMO22013–2014
Cashion CharlesOfficerSVP, Finance, CFO and Sec.82013–2017
COOPERATIVE GILDE HEALTHCARE II U.A.TenPercentOwner22013
EVNIN LUKETenPercentOwner22013
Foley ToddTenPercentOwner22013
GADICKE ANSBERTTenPercentOwner22013
HALE DAVID FDirector102013–2019
KAILIAN VAUGHN MTenPercentOwner22013
KLINGENSTEIN PAUL HDirector; Director,TenPercentOwner32013–2014
LACASSE LOUIS PDirector42013–2015
Malik ShahzadDirector,TenPercentOwner52013–2016
Mento Steven JDirector; Director,OfficerInterim President and CEO; President and CEO; President, CEO & Director182013–2023
MPM Asset Management Investors BV4 LLCTenPercentOwner22013
MPM ASSET MANAGEMENT INVESTORS BV5 LLCTenPercentOwner22013
MPM BioVentures IV GmbH & Co. Beteiligungs KGTenPercentOwner22013
MPM BioVentures IV GP LLCTenPercentOwner22013
MPM BioVentures IV LLCTenPercentOwner22013
MPM BioVentures IV QP LPTenPercentOwner22013
MPM BIOVENTURES V GP LLCTenPercentOwner22013
MPM BIOVENTURES V LLCTenPercentOwner22013
MPM BIOVENTURES V, L.P.TenPercentOwner22013
Perret Marc OlivierDirector,TenPercentOwner22013
Scopa James PaulDirector; Director,TenPercentOwner72013–2018
Spada Alfred P.OfficerEVP, R&D and CSO; See Remarks; SVP, R&D and CSO132013–2023
Vander Vort JohnTenPercentOwner22013
Van Wart HaroldDirector92013–2019
KISNER DANIEL LDirector152014–2023
Klassen PrestonDirector72014–2019
Hagerty David TOfficerEVP, Clinical Development62014–2019
Smith Edward F IIIOfficerSVP, Reg Affairs and QA52016–2019
RIPLEY DANIEL L.OfficerSVP, Bus Dev, P&A Mgmt42017–2019
LARUE WILLIAM RDirector42017–2019
VANDERTIE MICHELLE LOfficerVice President, Finance52017–2019
Marshall Keith WOfficerEVP, COO & CFO62017–2020
Scott Kathleen D.Director22019
Chang StephenDirector32020
Crean David HughDirector62020–2023
Jackson JonathanDirector; Director,TenPercentOwner62020–2023
Latterich MartinOfficerSee Remarks; SVP, Technical Operations52020–2022
Naughton Gail KOfficerSee Remarks32020–2021
Pascoe Richard WDirector,OfficerPresident, CEO & Director; See Remarks52020–2021person page Fuzzy
Satz BrianDirector62020–2023
Zhang YizhuoDirector32020
Knudson Susan A.OfficerCOO and CFO; EVP, CFO & Corp Secy; See Remarks72020–2023person page Fuzzy
Daniels MoyaOfficerSee Remarks32020–2021
Windham-Bannister Susan RichardsDirector42021–2023person page Fuzzy
Fuhrmann RochelleDirector42021–2023
Reyes JoyceOfficerSee Remarks42022–2023

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2022-07-26Histogen Inc.Biotechnology$5,000,000$5,000,00011
2020-11-18Histogen Inc.Biotechnology$189,208$189,20871

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Plan sponsorHISTOGEN, INC.CAForm 5500 (employee benefit plans)name and state
Federal award recipientHISTOGEN INCCAFederal spending (USAspending)name and state
Form D issuerHistogen Inc.CAForm D private offeringsname and state
Form D issuerHistogen Inc.CAForm D private offeringsCIK (EXACT)
Patent assigneeHistogen, Inc.CAPatents (USPTO)name and state
SEC filerHistogen Inc.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerHistogen, IncCATrademarks (USPTO)name and state
Form 5500 plan sponsorCONATUS PHARMACEUTICALS INC.EIN (EXACT)
Person pageRichard W PascoePeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director,Officer)
Person pageSusan A KnudsonPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer)
Person pageSusan Richards Windham-BannisterPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, CA first:

More with this interest.

In other datasets, the same topic (Health) in CA:

Interests: Pharmaceutical Preparations · Health